User profiles for Vida Ravanmehr
Vida RavanmehrBaylor College of Medicine Verified email at bcm.edu Cited by 551 |
The Monarch Initiative in 2019: an integrative data and analytic platform connecting phenotypes to genotypes across species
…, C Pilgrim, T Putman, V Ravanmehr… - Nucleic acids …, 2020 - academic.oup.com
In biology and biomedicine, relating phenotypic outcomes with genetic variation and
environmental factors remains a challenge: patient phenotypes may not match known diseases, …
environmental factors remains a challenge: patient phenotypes may not match known diseases, …
[PDF][PDF] KG-COVID-19: a framework to produce customized knowledge graphs for COVID-19 response
Integrated, up-to-date data about SARS-CoV-2 and COVID-19 is crucial for the ongoing
response to the COVID-19 pandemic by the biomedical research community. While rich …
response to the COVID-19 pandemic by the biomedical research community. While rich …
[PDF][PDF] Interpretable clinical genomics with a likelihood ratio paradigm
PN Robinson, V Ravanmehr, JOB Jacobsen… - The American Journal of …, 2020 - cell.com
Human Phenotype Ontology (HPO)-based analysis has become standard for genomic
diagnostics of rare diseases. Current algorithms use a variety of semantic and statistical …
diagnostics of rare diseases. Current algorithms use a variety of semantic and statistical …
[HTML][HTML] Semantic integration of clinical laboratory tests from electronic health records for deep phenotyping and biomarker discovery
Electronic Health Record (EHR) systems typically define laboratory test results using the
Laboratory Observation Identifier Names and Codes (LOINC) and can transmit them using Fast …
Laboratory Observation Identifier Names and Codes (LOINC) and can transmit them using Fast …
[HTML][HTML] GRAPE for fast and scalable graph processing and random-walk-based embedding
…, T Fontana, E Casiraghi, V Ravanmehr… - Nature Computational …, 2023 - nature.com
Graph representation learning methods opened new avenues for addressing complex, real-world
problems represented by graphs. However, many graphs used in these applications …
problems represented by graphs. However, many graphs used in these applications …
[PDF][PDF] Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells
…, L Deaton, T Cain, H Yang, V Ravanmehr… - Cell Reports …, 2023 - cell.com
Autologous anti-CD19 chimeric antigen receptor T cell (CAR T) therapy is highly effective in
relapsed/refractory large B cell lymphoma (rrLBCL) but is associated with toxicities that …
relapsed/refractory large B cell lymphoma (rrLBCL) but is associated with toxicities that …
KG-Hub—building and exchanging biological knowledge graphs
Motivation Knowledge graphs (KGs) are a powerful approach for integrating heterogeneous
data and making inferences in biology and many other domains, but a coherent solution for …
data and making inferences in biology and many other domains, but a coherent solution for …
[PDF][PDF] GraPE: fast and scalable Graph Processing and Embedding
Graph Representation Learning methods opened new possibilities for addressing complex,
real-world problems represented by graphs. However, many graphs used in these …
real-world problems represented by graphs. However, many graphs used in these …
An information theoretic approach to constructing robust Boolean gene regulatory networks
B Vasic, V Ravanmehr… - IEEE/ACM Transactions …, 2011 - ieeexplore.ieee.org
We introduce a class of finite systems models of gene regulatory networks exhibiting behavior
of the cell cycle. The network is an extension of a Boolean network model. The system …
of the cell cycle. The network is an extension of a Boolean network model. The system …
[PDF][PDF] Supervised learning with word embeddings derived from PubMed captures latent knowledge about protein kinases and cancer
V Ravanmehr, H Blau, L Cappelletti… - NAR genomics and …, 2021 - academic.oup.com
Inhibiting protein kinases (PKs) that cause cancers has been an important topic in cancer
therapy for years. So far, almost 8% of >530 PKs have been targeted by FDA-approved …
therapy for years. So far, almost 8% of >530 PKs have been targeted by FDA-approved …